At the invitation of STAR Protocols, RocRock Bio published a protocol for generating human CAR-engineered macrophages via Vpx - containing lentivirus, achieving over 95% transduction efficiency. This signifies RocRock's authority in CAR-M preparation and innovation, offering a reference for global CAR-M therapy research. RocRock has been dedicated to bio - medical technology R&D, especially in cell therapy, and has established a strong platform for chronic diseases. Current treatments for solid tumors are suboptimal, with even groundbreaking drugs like PD-1/PD-L1 antibodies only effective for some patients. CAR-M therapy has garnered attention for its unique properties. To overcome the challenge of macrophages' resistance to lentiviral vectors, RocRock introduced Vpx, enhancing infection efficiency by degrading SAMHD1. The comprehensive protocol covers all steps from cell separation to infection, guiding researchers in CAR-M preparation.
RocRock Bio has demonstrated remarkable potential in CAR-M preparation, evidenced by seven successful clinical trials. Yet, the company is far from complacent. It will continue to strengthen partnerships with research bodies worldwide, refine CAR-M preparation techniques, and explore innovations to provide more effective treatment options for patients. Concurrently, RocRock is committed to fulfilling its social responsibilities, ensuring broader public access to scientific advancements, and advancing the global health cause.
Drag & Drop Website Builder